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1887, Noccard-Mollereau, bovine mastitis 
1933, Group B Antigen  
1964, severe neonatal sepsis, Eickhoff et al N Eng J med 
Ø 1970,	N°1		in	neonatal	infecBons	
Gram positive cocci  
 Encapsulated 
 Catalase - 
 β-hemolytic 
 CAMP test + 
 Hippurate + 
 Esculine- 
 Orange pigment 
	
10 capsular serotypes (Ia, Ib, II-IX) 
  3 pilus types (P1, P2a & P2b) alone or 
combined  
Streptococcus agalactiae or GBS 
Rebecca Lancefield 1895-1981 
		 INTR TION & BURDEN 
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1887, Noccard-Mollereau, bovine mastitis 
1933, Group B Antigen  
1964, severe neonatal sepsis, Eickhoff et al N Eng J med 
Ø 1970,	N°1		in	neonatal	infecBons	
Streptococcus agalactiae or GBS 
		 INTR TION & BURDEN 
 Streptococcus agalactiae clones infecting 
humans were selected and fixed through the 
extensive use of tetracycline  
 
•  Genome-based phylogeny reveals the expansion of a few 
clones 
•  Human GBS belong mainly to a small number of TcR clones   
V.Dacunha, MR.Davies, …, C.Poyart and P.Glaser 
In Nat Commun. 2014 Aug 4;5:4544. doi: 10.1038/ncomms5544. 
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Group B streptococcal diseases in 
neonates 
§  Since the 1970s, leading cause of life-
threatening infections in newborns 
§  Neonatal illness/death 
§  Long-term disabilities 
§  Maternal morbidity  
§  Along pregnancy  
§  Peripartum 
§  Serious diseases among elderly and adults with 
underlying diseases 
§  Significant mortality 
		 INTR TION & BURDEN 
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GBS Neonatal Infections  
A. Schuchat, Clin Microb Rev 1998;11:497-513 
  
		 INTR TION & BURDEN 
8								INTRODUCTION	&	BURDEN															GUIDELINES															IAP	-SCREENING														VACCINE														CONCLUSION	bioMérieux 2015 /PM 
80 % EOD
   LOD                  & VLOD
GBS Neonatal Infections 	
A. Schuchat, Clin Microb Rev 1998;11:497-513 





















EOD : 80-90 % occur  
before  24 h
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GBS Neonatal Infections 
EOD LOD 



























Capsular serotypes All	(Ia,	III,	V)	 III,	mainly	
Hypervirulent	clone	ST17	/meningiBs	
		 INTR TION & BURDEN 
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Distribution (%) of capsular types of GBS isolated in 
Belgium from different groups of patients (1998-2007) 










Ia	 Ib	 II	 III	 IV	 V	 VI	-	VIII	 NT	
EOD	 LOD	 Adults	
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40 - 60 %60 - 40 %
GBS EOD vertical transmission 
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40 - 60 %60 - 40 %
96	-	98	%	
AsymptomaBc	
		 INTR TION & BURDEN 
GBS EOD vertical transmission 
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40 - 60 %
2 - 4 %
GBS EOD 










		 INTR TION & BURDEN 
GBS EOD vertical transmission 
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GBS maternal colonization 
Risk factor for early-onset disease (EOD) : 
vaginal GBS colonization at delivery 
 
§  GBS carriers*  
§  10 - 35 % of women (Be: 20-25%) 
§  Clinical signs not predictive 
§  Dynamic condition 
§  Intestinal reservoir 
§  Prenatal cultures late in pregnancy can predict 
delivery status 
*: Carriage not restricted to women ! 
		 INTR TION & BURDEN 
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Additional Risk Factors  
for Early-Onset GBS Disease 
§  Obstetric factors*:  
§  Prolonged rupture of  
membranes,  
§  Preterm delivery,  
§  Intrapartum fever 
§  GBS bacteriuria* 
§  Previous infant with GBS disease* 
§  Immunologic:  
§  Low specific IgG to GBS capsular 
polysaccharide 
*: No difference in occurrence either in GBS 
Positive or Negative women, except 
intrapartum fever 
Lorquet S., Melin P. & al. 
J Gynecol Obstet Biol Reprod 2005 
Risk  
factors 
		 INTR TION & BURDEN 
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GBS EOD - Belgian data 
§  Incidence 
§  1985 -1990: 3/1000 live births 
§  1999, estimation : 2/1000 live births 
§  2010, estimation : < 1/1000 live births  
§  Meningitis : 10 % 
§  Mortality : 5 -10 % 
§  60 % EOD (130 cases) : WITHOUT any maternal/
obstetric risk factor except colonization 
§  Prenatal screening 
§  Recto-vaginal cultures : 13-35 % GBS Positive 
P. Melin -  2001, 2007 - Reference laboratory for GBS.
		 INTR TION & BURDEN 
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Burden of neonatal  GBS early onset 
diseases in European countries 




Spain 2 (1996) to 0.45 
(2008)  
Lopez Sastre et al. 
Acta Pediatr 2005 
Belgium 3 (1985) to <1 
(2010) 
Melin, Indian J Med 
Res 2004 
Eastern Europe 0.2 - 4 Trijbels-Smeulders, 
Pediatr Infect Dis J 
2004 Western Europe 0.3 - 2 
The Netherlands  1.9 
Scandinavia 0.76 - 2 
Southern Europe 0.57 - 2 
Data assessing more accurately the true burden are needed 
 
-  Carriage rate ? 







		 INTR TION & BURDEN 
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Stages in the pathogenesis of GBS 
neonatal EOD : Bacterial & individual factors 
GBS  
pathogenesis 
Colonization : adhesion to epithelial cells 










-  C5a peptidase 
-  ….. Bacteria 
Peptidoglycan 
β-hemolysin, … 
IL1, IL6, TNF α, 
PGE2, TxA2 ,   
Brain barrier 




Phagocytes cells, CPS 
Antibodies, Complement 
		 INTR TION & BURDEN 
19								INTRODUCTION	&	BURDEN															GUIDELINES															IAP	-SCREENING														VACCINE														CONCLUSION	bioMérieux 2015 /PM 
Stages in the pathogenesis of GBS 
neonatal disease (EOD & LOD) 
Tozi A et al. 2011 http://dx.doi.org/10.1051/medsci/2011274010 
		 INTR TION & BURDEN 
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GUIDELINES FOR PREVENTION 
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Stages in the pathogenesis of GBS 
neonatal EOD : Bacterial & individual factors 
GBS  
pathogenesis 
Colonization : adhesion to epithelial cells 
different virulence factors (pili, scpB, …) 
 Intrapartum  antibioprophylaxis 
> 4 (2) hours before delivery 
Highly effective in preventing GBS EOD (1st clinical trials in late 80s) 
				GUIDELINES 
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Stages in the pathogenesis of GBS 
neonatal EOD : Bacterial & individual factors 
GBS  
pathogenesis 
Colonization : adhesion to epithelial cells 










-  C5a peptidase 
-  ….. 
Phagocytes cells, CPS 
Antibodies, Complement 
GBS vaccine 
« nearly within reach » 
				GUIDELINES 
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Prevention of perinatal GBS EOD	
§  Intrapartum antibiotics 
§  Highly effective at 
preventing EOD in 
women at risk of 
transmitting GBS to 
their newborns ( > 4 h) 
(clinical trials in late 80s) 
Who is  
the women  
at risk ? 
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Prevention of perinatal GBS EOD	




Main goal :  
§  To prevent 70 to 80 % of GBS EO cases 
Secondary : 
§  To reduce peripartum maternal morbidity 
				GUIDELINES 
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  Impact of prevention practices 
  Early- and Late-onset GBS Diseases in 
the 1990s, U.S. 
   CDC 1st Consensus   
   guidelines: 
• Screening  
• Risk-based 
Group B Strep 
Association 
formed  
  1st ACOG & AAP 
   statements 
           CDC draft  
guidelines published 
S. Schrag, New Engl J Med 2000 
Schrag S. et al. N Engl J Med 2002; 347:233-9 
 
Screening >50%  




No effect on GBS LOD 
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Why is Screening more protective 
than the risk-based approach ? 
Schrag	S.	et	al.	N	Engl	J	Med	2002;	347:233-9	
Broader coverage of « at-risk » population 
Ø  Captures colonized women without obstetric RF 
Ø  High level of compliance with recommendations 
Ø  Enhanced compliance with risk-based approach 
cannot prevent as many cases as universal 
screening 
				GUIDELINES 
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  Impact of prevention practices 
  Early- and Late-onset GBS Diseases, U.S. 
Incidence of early- and late-onset invasive group B streptococcal disease in 





















































department of health and human services
Centers for Disease Control and Prevention
Recommendations and Reports November 19, 2010 / Vol. 59 / No. RR-10
Morbidity and Mortality Weekly Report
www.cdc.gov/mmwr
Prevention of Perinatal Group B 
Streptococcal Disease
Revised Guidelines from CDC, 2010
Continuing Education Examination available at http://www.cdc.gov/mmwr/cme/conted.html
2010 
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CDC, USA, MMWR, Vol 59 
(RR-10) August 2010 
Endorsed by 
  - AAP  
  - ACOG 
 
            SHC, Belgium July 2003 
Revision ongoing 
department of health and human services
Centers for Disease Control and Prevention
Recommendations and Reports November 19, 2010 / Vol. 59 / No. RR-10
Morbidity and Mortality Weekly Report
www.cdc.gov/mmwr
Prevention of Perinatal Group B 
Streptococcal Disease
Revised Guidelines from CDC, 2010
Continuing Education Examination available at http://www.cdc.gov/mmwr/cme/conted.html
				GUIDELINES 
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European strategies 
for prevention of GBS EOD 
§  Intrapartum antibioprophylaxis recommended 
§  Screening-based strategy 
§  Spain, 1998, 2003, revised 2012 
§  France, 2001 
§  Belgium, 2003, revision ongoing 
§  Germany, 1996, revised 2008 
§  Switzerland, 2007  
§  Risk-based strategy 
§  UK, the Netherlands, Denmark 
§  No guidelines 
§  Bulgaria, … 
				GUIDELINES 
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Universal screening-based strategy for 
prevention of GBS perinatal disease 
Vagino-rectal GBS screening culture  at 35-37 weeks of gestation  
 
For ALL pregnant women 
> 1 Risk factor:  
   - Intrapartum fever > 38°C*** 
   -  ROM > 18 hrs 




























if NO if YES
Unless patient had a previous infant with GBS invasive disease  
 or GBS bacteriuria during current pregnacy 
 or delivery occurs < 37 weeks’ gestation * 
GBS Neg 
if  YES
GBS POS Not done, incomplete or 
unknown GBS result 
! Facultative !  
Intrapartum rapid GBS  test** 
				GUIDELINES 






Adhesion to a common protocol is a key of success 
Multidisciplinary collaboration is mandatory 
P. De Mol!
				GUIDELINES 
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P. De Mol!
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Intrapartum IV Antibio-Prophylaxis 
(CDC 2010, Belgian SHC 2003) 
				GUIDELINES 
§  Penicillin G 
§  5 millions U, IV initial dose, then 2,5 to 3 millions U IV every 4 
hours until delivery. 
§  Ampicilline   
§  2 g IV initial dose, then 1 g IV everye 4 h until delivery. 
§  Acceptable alternative , but broader spectrum, potential selection of R 
bacteria 
§  If penicillin allergy 
§  Patients at low risk for anaphylaxis 
§  Cefazolin, 2 g IV initial dose, then 1g IV every 8 h until delivery.  
§  Patients at high risk for anaphylaxis  
§  Clindamycin, 900 mg IV every 8 hours until delivery. 
§  If GBS resistant to clindamycin : use vancomycin, 1 g IV q12h 
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Intrapartum IV Antibio-Prophylaxis 
& antibiotherapy 
				GUIDELINES 
§  Intrapartum antimicrobial prophylaxis (IAP) 
§  Penicillins = first line drugs 
§  In case of IgE mediated allergy (risk of anaphylaxis) 
§  Clindamycin, if susceptible 
§  Vancomycin, if clindamycin resistant or unknown status 
§  Treatment of infections  
§  Penicillins = first line drugs 
§  +/- combination with aminoglycosides in severe 
infections 
§  According to site of infections 
§  Macrolides, clindamycine, fluoroquinolones 
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Concerns : Clinically relevant 
antimicrobial resistance 
§  Susceptibility to penicillin 
§  Very few « not S » isolates recently characterized 
in Japan  
§  Mutation in pbp genes, especially pbp2x  
§  MIC= 0.25 -1 mg/L 
§  No clinical impact ? 
Noriyuki Nagano et al, AAC 2008
§  Very few in the U.S. 
§  All labs should send to reference lab 
§  Any « non-S » isolate for confirmation 
§  All invasive isolates for resistance surveillance 
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Will penicillins remain the 
gold standard ? 
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GBS and non-S to β-lactams 
§  Existence and molecular mechanisms of 
clinical isolates with reduced Penicillin 
susceptibility (PRGBS) 
§  First report in Japan by Kimura K et al, AAC 2008 
§  Following reports from Japan, USA, Canada  
§  Penicillin MIC   0.25-1 mg/L 
§  Ceftizoxime MIC  4-128  mg/L 
Acquisition of amino-acid substitutions in PBP2X 
and in PBP1A 
à elevation of cephalosporins’MICs 
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PR GBS versus PR S.pneumoniae 
§  PR S.pneumoniae   
§  Penicillin MICs increased by acquiring various 
amino-acid substitutions in PBPs, including 
PBP1A and PBP2X 
§  Why should we not see the same in GBS? 
§  Risk of highly resistant cephalosporin GBS 
§  Risk of increase of MICs to penicillin 
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PR GBS detection 
à possibly unrecognized by standard 
antimicrobial susceptibility methods !! 
§  Recommended methods for initial screening 
§  3-Disk diffusion 
§  Oxacillin, ceftizoxime,  
§  Ceftibuten (no zone) 
§  MICs to oxacillin and ceftizoxime 
§  Usually high for PR GBS  
Kimura et al, J Clin Microbiol 2009 
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What do we know today about 
macrolide - lincosamide Resistance? 
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Resistance to macrolides/lincosamides 






















43								INTRODUCTION	&	BURDEN															GUIDELINES															IAP	-SCREENING														VACCINE														CONCLUSION	bioMérieux 2015 /PM 
Resistance to macrolides/lincosamides 






















Resistance to clindamycin :  
Constitutive or Inducible R  
à D-Test recommended 
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Resistance to macrolides/lincosamides 
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MLS acquired Resistance 
Phenotypes and genotypes 
§  Target modification (erm family genes) 
§  Constitutive MLS resistance  
§  Inducibe MLS resistance (D-zone test)  
§  Serotype associated (higher rates: IV, V > III > others) 
Cross resistance to macrolides, lincosamides and 
streptogramin B 
 
§  Active efflux (mefA gene) à M phenotype 
Resistance to 14- & 15- membered ring macrolides 
(as erythromycin and azithromycin) 
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MLS acquired Resistance 
Phenotypes and genotypes 
§  Target modification (erm family genes) 
§  Constitutive MLS resistance  
§  Inducibe MLS resistance  
Cross resistance to macrolides, lincosamides and 
streptogramin B 
§  Active efflux (mefA gene) 
Resistance to 14- & 15- membered ring macrolides (as 
erythromycin and azithromycin) 
§  Enzymatic inactivation or ? (lnu genes, lsa genes) 
§  Clindamycin resistance  
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Phenotypes L 
§  L phenotype 
§  Inactivation by lincosamide 
nucleotidyltransférases (lnu(B) and lnu(C) genes) 
§  New Zealand, Canada, USA, Asia, Argentina 
 
§  LSA or LSAP phenotype 
§  Cross resistance to lincosamides, streptogramin 
A and pleuromutilin 
§  lsa(C) gene 
§  New Zealand (Malbruny et al., AAC, 2011) 
§  Belgium (J.Descy et al, LISSSD abstract 100) 
§  0.6%  from1329 isolates (2008-2013) 
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§  Emergence of resistance is unavoidable 
§  But how fast ? 
§  Transmission of Resistant genes « in 
package » ! 
à Risk of increase of multi-resistance  
à Threat for both prophylaxis and therapy 
 
§  Emphasize the need for  
§  careful epidemiologic monitoring   
§  good clinical laboratory AST practice 
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Antibiotics About Resistance Epidemio. 
surveillance 
by Nat.Ref.C. 




•  Still very rare 
•  Possibly 
unrecognized 
Mandatory Initial screening 
by with 3-disks 
diffusion  





•  Globally on the rise 
•  National differences 
•  Evolution of genetic 
supports 




•  AST for E & C 
•  D-zone Test 
synergy testing 
if E R 
Already 
recommended 
Gentamicin  •  Emerging in some 
countries 








Fluoroquinolones •  Emerging in Asia 
•  Rare elsewhere 
Mandatory 
 
No special trick  
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Concerns about potential adverse / unintended 
consequences of prophylaxis 
 
§  Management of neonates 
§  Increase of unecessary evaluation 
§  Increase of unecessary antimicrobial treatments 
à Algorithm for secondary prevention of EOD 
among newborns 
§  Symptoms; maternal chorioamnionitis; 
prophylaxis; gestational age; time of rupture of 
membrane 
Rem.:  
80-90 % of GBS EOD are symptomatic < 24 h of live 
Management of the neonate at risk for early onset Group B streptococcal disease (GBS EOD): new paediatric 
guidelines in Belgium 
L. Mahieu, J.-P. Langhendries, V. Cossey, C. De Praeter, P. Lepage, P. Melin - Acta Clinica Belgica 2014:313-9 
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Remaining burden of GBS EOD 
Missed opportunities 
In spite of universal screening prevention 
strategy 
In spite the great progress 
 Cases still occur 
§  Among remaining cases of EOD 
§  Some may be preventable cases 
§  Missed opportunities for (appropriate) IAP 
§  False negative screening 
Van Dyke MK, Phares CR, Lynfield R et al. N Engl J Med 2009 
CDC revised guidelines 2010 
Poyart C, Reglier-Poupet H, Tazi et al. Emerg Infect Dis 2008 
DEVANI project, unpublished data 2011 
 
				GUIDELINES 
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SCREENING  
FOR GBS COLONIZATION 
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Antenatal GBS culture-based 
screening 
Goal of GBS screening 
To predict GBS vaginal (rectal) colonization at the 
time of delivery 
§ 	Critical factors influencing accuracy 
§  Swabbed anatomic sites 
§  Timing of sampling 




§  Non-culture  
 SCREENI G 





Yancey MK et al. Obstet Gynecol 1996;88:811-5 
OpBmal	Bme	for	screening	
35-37	weeks	gestaBon 
 SCREENI G 
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Culture-based	screening	done	1	to	5	or	>	6	weeks	before	
delivery	(Yancey,	860	cases;	Melin,	531	cases)	
Yancey MK et al. Obstet Gynecol 1996;88:811-5 
OpBmal	Bme	for	screening	
35-37	weeks	gestaBon 
Melin, 13-16% GBS Pos 
PPV= 56% 
NPV= 95% 
or 5% False negative  
or 30% of  GBS pos in 
labor not detected with 
prenatal screening ! 
 SCREENI G 
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§  WHEN   35-37 weeks 
§  WHO  ALL the pregnant women 
§  Specimen   Vaginal + rectal swab(s) 
§  Collection  WITHOUT speculum 
§  Transport  Transport/collection device/condition 
 (non nutritive medium: Amies/Stuart or Granada 
 like tube) (type of swab)(Length and T°) 
§  Request form  To specify prenatal « GBS » 
 screening  
§  Laboratory procedure 
Crucial conditions to optimize 
SCREENING 
(CDC 2010 - Belgian SCH 2003) 
 SCREENI G 
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From direct plating on blood agar 
Evolution of culture methods 	
Use of selective enrichment broth 
§  To maximize the isolation of GBS 
§  To avoid overgrowth of other organisms 
 
Use of differential agar media 
Recommended by some European guidelines (+ CDC 2010) 
 
 1983, 1992                            2005       2007 
GRANADA 
(M.de la Rosa,JCM) 
Strepto B 
Select  
StreptoB ID  
Pigment-based 	 	 																						Chromogenic	media	




63								INTRODUCTION	&	BURDEN															GUIDELINES															IAP	-SCREENING														VACCINE														CONCLUSION	bioMérieux 2015 /PM 
Which agar or which combination? 
+/- Blood agar 
 
Workload - costs - extra-testing - non β-hemolytic  
GBS detection  to be considered 
 SCREENI G 
= GBS probable    = GBS      = GBS probable 
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Reading and processing of the cultures 
Identification: Group B Antigen or MALDI-TOF MS 
 SCREENI G 
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§  WHEN   35-37 weeks 
§  WHO  ALL the pregnant women 
§  Specimen   Vaginal + rectal swab(s) 
§  Collection  WITHOUT speculum 
§  Transport  Transport/collection device/condition 
 (non nutritive medium: Amies/Stuart or Granada 
 like tube) (type of swab)(Length and T°) 
§  Request form  To specify prenatal « GBS » 
 screening  
§  Laboratory procedure 
Crucial conditions to optimize 
SCREENING 
(CDC 2010 - Belgian SCH 2003) 
 SCREENI G 
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Transport-collection system & transport-storage condition 
§  Specimen storage in transport medium and detection of group B 
streptococci by culture. 
 Rosa-Fraile M. et al. J Clin Microbiol 2005, 43: 928-930 
Ø  Belgian Guidelines (2003, SHC) 
“Specimens should be placed in a non-nutritive transport medium (e.g., Amies or Stuart's 
without charcoal). In these conditions, viability of GBS is warranted for at least 48 h at 
room temperature or in a fridge (2 - 8°C).   
Specimen labels should clearly identify that specimens are for group B streptococcal 
culture.  Swabs should reach the lab within 48 h of collection.” 
Crucial conditions to optimize 
SCREENING 
 SCREENI G 
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IMPROVEMENT OF TRANSPORT CONDITION OF 
SWABS FOR GROUP B STREPTOCOCCAL (GBS) 
SCREENING   
 P. Melin, M. Dodémont, G. Sarlet, R. Sacheli, et al. 
National Reference Centre for GBS, University Hospital of Liège, Liège, Belgium 
To sustain viability 
Whatever is storage T° for a few days 
Use of a selective enrichment Lim broth as 
transport media 
 
17#DIP 2015- PMelin - CHULg 
From direct plating on blood agar 
Evolution of culture methods #
Use of selective enrichment broth (Lim broth, e.g.) 
!  To maximize the isolation of GBS 
!  To avoid overgrowth of other organisms 
 
Use of differential agar media 
Recommended by some European guidelines (+ CDC 2010) 
 
 1983, 1992                            2005       2007 
GRANADA 
(M.de la Rosa,JCM) 
Strepto B 
Select  
StreptoB ID  
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  >104 
ConBnuous	decrease	
Granada tube: not shown, dramatic drop at 48-72h 
72								INTRODUCTION	&	BURDEN															GUIDELINES															IAP	-SCREENING														VACCINE														CONCLUSION	bioMérieux 2015 /PM 
Transport conditions to be 
recommended for optimizing GBS 
antenatal screening 
 Belgian Health Superior Council, 2015 
§  Transport system 
§  Use of a selective enrichment Lim broth with a flocked swab 
 (BD, Copan, bioMérieux, i.e.) 
§  Transport and storage condition 
§  At RT° (up to 35°C)  
§  As soon as possible  
§  Viability sustained at least 4 days  
§  Remark 
§  If use of Amies or Stuart medium (non nutritive medium)  
§  To be processed as soon as possible within 24 hours (max 48 h)  
 SCREENI G 
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Prenatal culture-based 
screening: Limiting factors 
§  Positive and negative predictive values 
§  False-negative results 
§  Failure of GBS culture  (oral ATB, feminine hygiene) or 
new acquisition 
§  Up to 1/3 of GBS positive women at time of delivery 
§  Continuing occurrence of EO GBS cases 
§  False-positive  
§  Positive prenatal screening /negative at time of delivery 
§  Unnecessary IAP 
Need for more accurate	predictor	of		
intrapartum	GBS	vaginal	colonizaBon	
 SCREENI G 
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Prenatal culture-based 
screening: Limiting factors 
§  Unknown GBS status at presentation for 
delivery 
§  Screening performed but result not available 
§  Women with no prenatal care 
Risk based strategy  
•  60% at GBS risk not identified 
•  > 10% of unnecessary IAP 
Need for rapid accurate	predictor	of		
intrapartum	GBS	vaginal	colonizaBon	
 SCREENI G 
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Alternative to GBS prenatal 
screening: intrapartum screening 
Theranostic approach 
Turnaround time 








30-45 minutes, 24 hrs/7 d, robust 
Benitz et al. 1999, Pediatrics, Vol 183 (6) 





•  Sensitivity > 90% 
•  Specificity > 95% 
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Towards	«	European	Consensus	»	
    Decision taken by a European working party 
(Neonatologists, obstetricians, microbiologists) 
including countries with screening-based IAP, with risk-
based IAP strategies or nothing (June 2013, Florence, Italy) 
Main guidelines 
§  Universal screening at time of delivery 
§  POCT with high PPV and NPV 
§  Real time PCR or other methods 
§  TAT < 1 hour 
§  IAP for all GBS positive pregnant women  
§  documented by intrapartum testing (or late pregnancy test if 
performed) 
§  Late pregnancy prenatal screening in known penicillin allergic 
women  
§  Determination of clindamycin susceptibility if GBS positive screening 
 SCREENI G 
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§  Inclusion of women without prenatal screening/care 
§  Identification of women with change of GBS status after 35-37 
wks gestation 
§  Increased accuracy of vaginal GBS colonization status at time 
of labor & delivery 
§  No antimicrobial susceptibility results (in case of penicillin IgE 
mediated allergy) 
 
Intrapartum screening theranostic 
approach: expected advantages 
IAP addressed to right target 
§  Reduction of inappropriate/unnecessary IAP 
§  Broader coverage of « at GBS risk women »  
Improvement of prevention  
 SCREENI G 
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Real Time PCR for intrapartum 
screening 
§  Advance in PCR techniques & development of 
platforms 
§  BD GeneOhmTM Strep B Assay (+/- 1 hr) (in laboratory) 
§  Xpert GBS, Cepheid (35-45 min) (can be performed as a POCT)  
 SCREENI G 
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Required analytical specification 
for rapid intrapartum test 
§  High sensitivity and specificity  
§  Minimum 90% and 95% respectively 
§  Full automation with integrated internal 
controls 
§  Easy to perform and interpret by nurses 
§  Time to result: < 1 hour 
§  24 h / 7 days availability 
 
Di Renzo G, Melin P et al. Intrapartum GBS screening and antibiotic prophylaxis : 
a European consensus conference. J Matern Fetal Neonatal Med 2014;27:1-17 
 SCREENI G 
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Xpert® GBS for intrapartum screening 
§  Real Time PCR on GeneXpert system 
§  Amplification of a conserved region adjacent to the cfb gene 
of GBS 
§  On vaginal or vagino/rectal swab 
§  Fully automated 
§  Easy handling (2 min hands on time) 
§  Result in 35-45 minutes 
§  a sample-processing control (SPC)  
§  to monitor processing conditions 
§  internal control (IC) 
§   to monitor PCR conditions and the absence of reaction inhibition 
 SCREENI G 
82								INTRODUCTION	&	BURDEN															GUIDELINES															IAP	-SCREENING														VACCINE														CONCLUSION	bioMérieux 2015 /PM 
Xpert® GBS for intrapartum screening 
(selected paper amongst many others) 
Diagnostic Accuracy of a Rapid Real-Time Polymerase Chain 
Reaction Assay for Universal Intrapartum Group B Streptococcus 
Screening  
Najoua El Helali, Jean-Claude Nguyen, Aïcha Ly, Yves Giovangrandi and 
Ludovic Trinquart   
Clinical Infectious Diseases 2009;49:417–23 
 
§  968 Pregnant women  
§  Intrapartum Xpert GBS, Cepheid  (performed in lab) 
§  vs intrapartum culture      antenatal culture (French recom.) 
              (vaginal swab/CNA-BA) 
§  Sensitivity   98.5% 
§  Specificity   99.6% 
§  PPV     97.8%    PPV    58.3% 
§  NPV     99.7%    NPV    92.1% 
 SCREENI G 
83								INTRODUCTION	&	BURDEN															GUIDELINES															IAP	-SCREENING														VACCINE														CONCLUSION	bioMérieux 2015 /PM 
Xpert® GBS for intrapartum screening 
(selected paper amongst many others) 
Cost and effectiveness of intrapartum group B streptococcus 
polymerase chain reaction screening for term deliveries. 
El Helali N, Giovangrandi Y, Guyot K, Chevet K, Gutmann L, Durand-
Zaleski I 
Obstet Gynecol 2012 Apr;119 (4):822-9 
 
           2009               2010  
Antenatal screening    Xpert GBS intrapartum screening 
        Performed by midwives as a POCT !! 
11.7% GBS POS     16.7% GBS POS 
        Less GBS EOD & less severe 
 
                        Cost neutral per delivery 
 SCREENI G 
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Xpert® GBS 
POC test in the delivery room study 
Objectives 
1.  To assess the practical aspects and analytical 
performances 
§  Tests performed by midwives 
§  Evolving team of +/- 50 midwives  
§  For screening all women at onset of labor 
 
2.  To evaluate the cost-effectiveness of the 
intrapartum screening strategy 
    




 SCREENI G 
Study in CHU Liège / UZ Antwerp, Belgium (900 patients) 
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Real-Bme	PCR,	very	promising,	BUT	…	
§  Rapid, robust & accurate technology 
§  Still an expensive technology (specific equipment) 
§  Cost effective ?  
§  Need for more cost-effective clinical study à 2014-2015 CHULg & UIA 
§  Logistic 
§  24 hours 7 days 
§  In the lab? 
§  In the obstetrical department as a POCT ? 
§  In combination with prenatal screening strategy ? 
§  CDC 2010 : for women with premature delivery or no prenatal care 
§  No antimicrobial result  
§  In the future detection of R genes, but mixed microbiota ! 
 SCREENI G 
86								INTRODUCTION	&	BURDEN															GUIDELINES															IAP	-SCREENING														VACCINE														CONCLUSION	bioMérieux 2015 /PM 
Real-Bme	PCR,	very	promising,	BUT	…	
 SCREENI G 
Xpert® GBS POCT in the delivery room 
 
§  Theoretical superior clinical value  
§  versus antenatal screening  
  
§  Looks like easy to perform, BUT … 
§  Careful training of midwives 
§  High turn-over in midwives team 
§  Performances to be verified on EACH site ! 
§  To be supervised closely by the lab 
§  Need for a internal specimen control 
§  Role of excess of mucus ? 
  
87								INTRODUCTION	&	BURDEN															GUIDELINES															IAP	-SCREENING														VACCINE														CONCLUSION	bioMérieux 2015 /PM 
Real-Bme	PCR,	very	promising,	BUT	…	
 SCREENI G 
Xpert® GBS POCT in the delivery room 
 
        
Not ready as a standalone screening 
§  High specificity but varying sensitivities ! 
§  Could be combined with risk factor strategy ?? 
§  Some expected improvements to secure the result  AND 
the patient management 
 
 
88								INTRODUCTION	&	BURDEN															GUIDELINES															IAP	-SCREENING														VACCINE														CONCLUSION	bioMérieux 2015 /PM 
VACCINE 
VAC I  
Prevention of GBS EOD and LOD 
Prevention of maternal diseases 
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Maternal GBS immunization 
Could maternal immunization be an 
alternative ? 
 
§  Protection against both EOD & LOD ? 
§  Bypassing concerns related to antimicrobial 
resistance ? 
§  Cost-effectiveness ? 
§  Adjunctive to screening & IAP ? 
VAC I  
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Lancefield’s observations 
§  Demonstration of protection against lethal GBS 
infection in a mouse model by antibodies to the CPS 
of GBS 





Long-standing data supports protection of maternal anti-CPS Ab	
VAC I  
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Background 
Long-standing data supports protection of maternal anti-CPS Ab	
§  Correlate between maternal low level of CPS type Ab  
(III, Ia & Ib) at time of delivery and risk for development 
of GBS EOD 
§  Human serum containing sufficient concentrations of 
Ia, Ib, II, III and V CPS-specific IgG promotes efficient 
opsonization & phagocytosis of homologous strain in 
vitro and protection from experimental infection in vivo. 
 
Baker C et Kasper D, 1976, NEJM 
 
 
VAC I  
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Background 
First generation of CPS vaccine	
¤ Disappointment from studies of uncoupled first 
generation purified native GBS CPS vaccines in 
healthy adults 
¤ Demonstration of  feasibility of vaccine prevention of 
GBS disease 
¤ Need for improvement of immunogens 
¤ Success story of polysaccharide-protein conjugate 
vaccine technology in preventing Hi b and 
S.pneumoniae infections in infants 
 
 
VAC I  
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Background	
§  Expectation of polysaccharide-protein 
glycoconjugates 
§  T cell-dependent response 
§  Immunological memory & long term protection 
§  Predominantly IgG1 subclass à improved 
transplacental transport 




VAC I  
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Maternal vaccination allows 
infant protection 	
§  Placental transfer increases markedly > 32 weeks 
 
 
Vaccine for pregnant women: 
 Likely the most effective, sustainable and cost 
effective approach 
 
VAC I  






NN fusion protein 
VAC I  
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GBS Vaccines, since the 1980s   
Challenges 
Native capsular polysaccharide vaccines (1st gen) 
§  10 serotypes 
§  Different distributions 
§  EOD, LOD, invasives infections in adults 










Ia	 Ib	 II	 III	 IV	 V	 VI	-	VIII	 NT	
EOD	 LOD	 Adults	
VAC I  
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GBS Vaccines, since the 1980s   
Challenges 
Native capsular polysaccharide vaccines (1st gen) 
§  10 serotypes 
§  Different distributions 
§  EOD, LOD, invasives infections in adults 
§  Geographically, along time, ATB  pressure 
Conjugated vaccines (2nd gen)  
(Channing laboratory, Harvard medical school, Boston) 
§  CPS III-Tetanus Toxoid 
§  Monovalent Ia, Ib, II and V CPS –TT 
§  Tested for immunogenicity in healthy adults 
§  Multivalent conjugated vaccines Ia, Ib, (II), III 
(and V) 
VAC I  
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GBS Vaccines, since the 1980s   
Challenges 
Capsular polysaccharide - TT vaccines 
Capsular polysaccharide – CRM197 vaccines 
(Second generation) 
 
§  Dosage and route of administration 
§  Immune response 
§  Duration of immunity and protection 
§  Safety studies 
VAC I  
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GBS Protein-based Vaccine 
§  Ag = Surface proteins 
§  Cross protection against different serotypes 
§  Better immunogenicity 
§  Humoral response T-cell dependent   
    = long lasting immunity 
 
GBS Vaccines, since the 1980s   
Challenges 
VAC I  
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Protein  Protective Ab  associated serotypes 
  (in mouse) 
Alpha-like proteins   
    Alpha  Yes    Ia, Ib et II 
    Alp1      Ia 
    Rib  Yes    III 
    Alp2  Yes    V, VIII 
    Alp3  Yes    V, VIII 
Beta C protein  Yes    Ib 
C5a peptidase  Yes    All 
Sip (1999)  Yes    All 
BPS  Yes    All 
Sip = Surface Immunogenic Protein (Brodeur, Martin, Québec)  
BPS= Groupe B Protective surface Protein 
Protein-based Vaccines 
VAC I  
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Protein-based Vaccines 
Reverse vaccinology approach 
Knowledge of complete GBS genome 
 
§  Comparaison of genomes from 8 different 
GBS serotypes (Novartis) 
D.Maione et al, Science 2006 
§  312 surface proteins were cloned 
§  4  provide a high protective humoral response in 
mouse 
§  Sip and 3 others 
§  The 3 other proteins = « pilus like structures » 
§  PI 1, PI 2a & 2b 
 
VAC I  
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GBS « pilus like structure » 
§  Highly immunogenic proteins 
§  Elicit protective and functional (opsonophagocytosis) 
antibodies 
§  Virulence factor 
§  Adhesion 
§  Transcytose through cells 
VAC I  
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Protein-based Vaccines 
GBS-NN fusion protein 
From Rib and AlphaC surface proteins of GBS 
§  Based on novel vaccine epitopes identified in the N-terminal 
regions of the Rib and AlphaC surface-proteins of GBS 








Rib and AlphaC surface proteins of GBS GBS-NN Fusion protein 
Immunodominant Repeats Non-immunodominant Highly Immunogenic 
Cell Host & Microbes 2, 427-434, 2007 
VAC I  
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Protein-based Vaccines 
GBS-NN fusion protein 
From Rib and AlphaC surface proteins of GBS 
§  Based on novel vaccine epitopes identified in the N-terminal 
regions of the Rib and AlphaC surface-proteins of GBS 
§  Vaccine candidate is a non-glycosylated fusion protein 
§  Highly immunogenic and anti-GBS-NN antibodies more 
protective than antibodies to full-length proteins 
 
 
A novel protein-only, single component, GBS  
vaccine covering 95% of clinical isolates 
VAC I  
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CANDIDATE VACCINES 
What is ongoing in 2015? 
CRM-Conjugate CPS 
NN Fusion protein 
Cost effectiveness studies 
VAC I  
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Novartis GBS Vaccine 
Trivalent glycoconjugate vaccine 
§  CRM conjugated CPS Ia, Ib and III 
§  Trivalent conjugate coverage: 79 % globally 
§  Phase I completed, and Phase II ongoing 
Planned start 2015 
(EU/US/Global) 
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Minervax GBS Vaccine 
Single component NN fusion protein 
§  Anticipated coverage : 95% of isolates 
§  Clinical trial in healthy adults : Q2-2015 
§  EU funding FP7 Programme HEALTH for the 
development of a novel innovative GBS vaccine 
candidate 
§  Other sources of funding 
VAC I  
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Vaccine 31S (2013) D1– D2
Contents lists available at ScienceDirect
Vaccine
jou rn al hom ep age: www.elsev ier .com/ locat e/vacc ine
Editorial
Introduction:  Addressing  the  challenge  of  group  B  streptococcal  disease
Towards the end of the 20th century, progress in vaccine devel-
opment technology led to the availability of conjugate vaccines
for the most common causes of bacterial sepsis and meningitis in
children including vaccines for Haemophilus influenzae type b, the
pneumococcus and meningococcus serotypes A, C, W-135 and Y
[1]. Recently a new vaccine for meningococcus serogroup B devel-
oped by reverse vaccinology has been approved by the EMA. These
advances in technology have been great advances in our ability to
prevent sepsis and meningitis in children.
On a parallel track, programmatic advances in the use of existing
vaccines have provided the opportunity to protect vulnerable pop-
ulations such as newborn infants and pregnant women. Although
maternal immunization with tetanus toxoid in developing coun-
tries has been recommended by WHO  for decades and has greatly
reduced the risk of neonatal tetanus, more recently immunization
of pregnant women has been recommended against influenza to
protect the mother and the infant [2]. In fact, influenza immuniza-
tion in pregnancy has been shown to have broad benefits to the
mother and infant including increased birth weight in infants born
to immunized mothers [2]. In addition, maternal pertussis immu-
nization during pregnancy is now routinely recommended in the
United States to protect newborns against this disease. Since infant
immunization with pertussis can not provide effective protection
to the infant until their second dose at four months of age and since
the highest morbidity and mortality of pertussis is in the first few
months of life, this was felt to be the only possible strategy to pro-
vide protection to these infants [3]. Importantly, these programs
have demonstrated not only that maternal immunization during
pregnancy is feasible, but also that it is a safe and effective vac-
cination strategy. However, the tetanus, influenza and pertussis
programs all have one thing in common: these programs utilize
vaccines that were developed and initially evaluated for use in
adults and older children and were then introduced into pregnant
women at a later date. To date, no vaccine has been approved and
licensed for use that has been specifically designed and targeted for
use in pregnant women.
With vaccine advances that have controlled or virtually elim-
inated the risk of Hib, pneumococcal and meningococcal disease
in children, the major cause of meningitis and sepsis in childhood
in developed countries and a major cause in all countries is now
the group B streptococcus or Streptococcus agalactiae (GBS). The
most widely recognized GBS disease occurs in newborns and young
infants with approximately half of this disease occurring within the
first hours of life (early onset disease) and the remainder occurring
after the first week but within the first 90 days (late onset disease).
The disease incidence varies by country but can be as high as 3 cases
per 1000 live births [4] with mortality ranging between 10 and 50%
even with modern neonatal intensive care [5]. It is important to
note that while programs which screen pregnant women for GBS
colonization and then institute intrapartum antibiotic prophylaxis
in those testing positive for GBS have been effective in reducing the
risk of early onset diseases in infants most notably in the US,  these
programs are not optimal both because the coordinated high level
of health care management is not available in developing countries
and importantly these programs only impact early onset GBS dis-
ease and have no effect on the remaining 50% of the total disease
burden in infants accounted for by late onset disease.
Moreover, there is increasing evidence that GBS is a cause
of maternal infections including urinary tract infections and
chorioamnionitis which result in maternal morbidity during preg-
nancy and are a risk factor for prematurity [6]. Recently it has been
demonstrated that selected strains of GBS lacking the hemolysin
repressor CovR/S accelerate failure of the amniotic barrier and
allow GBS to penetrate the chorioamniotic membrane barrier and
gain access to the fetus [7]. This provides a pathophysiologic basis
for the previously demonstrated ability of GBS  to cause maternal
chorioamnionitis as well as to gain access to the fetus and cause
early onset disease.
Thus a GBS vaccine administered to pregnant women during
pregnancy would have the potential to prevent the morbidity of
GBS infections in the mother with their associated risk of prematu-
rity as well as to protect the infant against both early and late onset
disease through passive acquired antibody.
It has been known for some time that antibody against the GBS
capsular polysaccharide in mothers is correlated with decreased
risk of disease in their infants [8]. This protection is serotype spe-
cific with most disease being due to serotypes Ia, Ib, III and to a
lesser extent serotype V. Novartis Vaccines has developed a vac-
cine containing CRM197 conjugates of capsular polysaccharides Ia,
Ib and III. This vaccine has been shown to be safe and immuno-
genic in both pregnant and non-pregnant women and to provide
IgG anti-capsular antibody to infants born to immunized pregnant
women through transplacental passive transfer (Novartis Vaccines
and Diagnostics, unpublished data). Preparation for a phase III effi-
cacy trial to evaluate the effectiveness of maternal immunization
with a trivalent GBS glycol-conjugate in the prevention of both early
and late onset GBS disease in their newborns is now underway.
In July 2012, a symposium was  held in Siena, Italy to discuss
the nature of Group B Streptococcal disease in the newborn, to
review current global disease burden and to discuss the need to
effective interventions which would be applicable in both devel-
oped and developing countries. The papers in this supplement to
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GBS	vaccine	-	Conclusion	
§  CPS-glycoconjugate vaccine 
§  3 to 5-valent glycoconjugate vaccine (Ia, Ib, II, 
III and V) 
§  CPS-CRM197 / Pili vaccine 
§  NN-fusion protein vaccine 
§  Immunogenicity 
§  Safety 
§  Efficacy determination ongoing 
§  Impact on colonization : unknown 
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Maternal	GBS	immunizaBon	
Conclusion	
§  Immunization at 28-32 weeks 
§  Prevention at least 85% of invasive 
GBS disease in neonates and young 
infants 
§  Potential reduction  
§  of incidence of maternal invasive GBS 
infection 
§  of premature births, stillbirths related 
to GBS infection 
§  Cost-effective in high and low 
income countries 
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CONCLUSION 
Take home messages 
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In Europe, as globally	
Neonatal GBS diseases  
§  EOD and LOD, a public health concern 
§  IAP efficient for prevention of EOD 
§  Best strategy still a matter of debate  
§  Not 100% efficient 
§  No effect on LOD 
§  IAP not widely recommended 
§  Towards European consensus 
§  Need better data assessing more 
accurately the true burden 
GBS vaccine eagerly expected  
§  Appears to be within reach  
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Summary	
“Screening” Prevention strategies 
 
§  Culture-based GBS prenatal 
screening 
§  To optimize critical factors 
§  Improved by selective differential agars 
§  False +/False - ! 
§  Expected improvement from transport system 
§    
§  Rapid intrapartum screening 
§  Real time PCR 
§  Yes but costs, logistic, … 
§  Need for more clinical and cost effectiveness trials 
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